- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07755007
Pneumatic Tube System Versus Personnel Transport and the Hemolysis Index of Emergency Department Blood Samples: A Randomized, Split-Sample, Single-Blind Trial (PTS-HEMO-ED)
Hemolysis is the most common pre-analytical error in emergency department (ED) laboratory specimens and can lead to false elevation of intracellular analytes (potassium, LDH, AST, hemoglobin), resulting in misdiagnosis and unnecessary testing. Blood samples in the ED are transported to the laboratory either by pneumatic tube systems (PTS) or manually by personnel. Although PTS shortens turnaround time, the forces generated during transport may damage erythrocyte membranes and promote hemolysis. Evidence on whether PTS increases hemolysis compared with personnel transport is inconsistent, partly because existing studies use parallel-group designs that cannot control for between-subject biological variability, and partly because findings differ across PTS brands and configurations. The Sumetzberger Power Control PTS installed at Marmara University Pendik Training and Research Hospital (speed 4-5 m/s, 120 m, cushioned capsule) has not been prospectively validated for hemolysis risk. This study uses a randomized, split-sample (within-patient matched), single-blind design in which two simultaneously drawn yellow-cap tubes from the same patient are randomly allocated, one to PTS and one to personnel transport, thereby eliminating between-patient variability. The primary outcome is the Hemolysis Index (HI) category (ordinal scale 0-5 corresponding to free hemoglobin thresholds of <50, 50-99, 100-199, 200-299, 300-500, and >500 mg/dL). Secondary outcomes include the rate of clinically significant hemolysis (HI >= 1 / free Hb >= 50 mg/dL) and the correlation between transport time and HI.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
PNEUMATIC TUBE SYSTEM TECHNICAL SPECIFICATIONS
The installed pneumatic tube system is a Sumetzberger Power Control system (Sumetzberger, Austria). The transit line length between the Emergency Department phlebotomy station and the central clinical laboratory is approximately 120 meters. System operating speed is set at 4-5 m/s. Transport capsules are cushioned with internal foam padding to minimize mechanical impact forces. Average transit duration ranges between 50 and 90 seconds.
BLOOD COLLECTION PROTOCOL
Blood collection is performed by trained emergency department phlebotomists using standard venipuncture technique. Tubes are drawn from a single venipuncture in the standard order of draw: (1) blue-cap coagulation tube, not used in the study; (2) yellow-cap serum separator tube #1; (3) yellow-cap serum separator tube #2; (4-5) any additional clinically indicated tubes, not used in the study. The two yellow-cap serum separator tubes are dispatched simultaneously by the two transport routes and are analysed simultaneously on arrival at the laboratory, so that waiting time does not act as a pre-analytical variable.
RANDOMIZATION AND ALLOCATION CONCEALMENT (CONSORT 2025 Items 15-17)
Allocation is by computer-generated block randomization with a block size of four. The allocation sequence assigns each participant to Sequence A (tube #1 to the pneumatic tube system, tube #2 to personnel transport) or Sequence B (tube #1 to personnel transport, tube #2 to the pneumatic tube system). The sequence is held in sealed, opaque, sequentially numbered envelopes that are opened in order at the time of enrolment. This scheme balances any effect of tube draw order across the two transport routes.
BLINDING (CONSORT 2025 Item 12b)
Tubes are labeled with standardized participant study identifiers and tube sequence numbers (Tube #1 and Tube #2) without indicating transport allocation. Laboratory technicians operating the automated analyzer and assessing the Hemolysis Index remain fully blinded to transport allocation. Clinicians and investigators are not blinded.
WITHDRAWAL CRITERIA
A participant's tube pair is withdrawn from analysis if pneumatic transport cannot be completed because of system failure, if a tube is broken or otherwise cannot be analyzed, or if the participant withdraws consent.
HARMS (CONSORT 2025 Item 27)
No intervention is applied to the participant. Both tubes are drawn from the venipuncture already required for routine clinical care, and no additional venipuncture or other invasive procedure is performed. No participant-level adverse events are therefore anticipated and no harms outcome measure is specified.
PATIENT AND PUBLIC INVOLVEMENT (PPI) STATEMENT (CONSORT 2025 Item 8)
Patients or members of the public were not involved in the design, conduct, reporting, or dissemination plans of this research. PPI was deemed non-applicable given the technical, pre-analytical nature of this laboratory quality evaluation study.
DATA SHARING STATEMENT (CONSORT 2025 Item 4)
De-identified individual participant data collected during the trial will be made available upon reasonable request to the corresponding investigator following publication.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Emir Ünal, Assistant Professor
- Telefonnummer: +905327766010
- E-post: emirunal@gmail.com
Studer Kontakt Backup
- Navn: Emir Ünal, Assistant Professor
- E-post: emirunal@gmail.com
Studiesteder
-
-
Pendik
-
Istanbul, Pendik, Tyrkia (Türkiye), 34899
- Rekruttering
- Marmara University Pendik Training and Research Hospital
-
Ta kontakt med:
- Emir Ünal
- Telefonnummer: 05327766010
- E-post: emirunal@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults aged 18 years or older
- Presenting to the emergency department of Marmara University Pendik Training and Research Hospital
- Venous blood draw required for routine clinical care, allowing two yellow-cap (serum separator) tubes to be drawn from the same venipuncture
- Written informed consent provided by the participant or, where the acute clinical condition of the participant prevents this, by a legal representative
Exclusion Criteria:
- Known underlying hemolytic disorder (e.g., hemolytic anemia, sickle cell disease, G6PD deficiency, autoimmune hemolytic anemia, or TTP/HUS)
- Macroscopic hemolysis visible in the sample tube immediately after phlebotomy
- Age younger than 18 years
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: PTS-First Sequence
Participants from whom two yellow-cap serum separator blood tubes are drawn simultaneously. Tube #1 (first drawn) is transported via the pneumatic tube system (PTS), and Tube #2 (second drawn) is transported by manual personnel. Both tubes are dispatched simultaneously. |
Blood sample transport using the Sumetzberger Power Control pneumatic tube system (Sumetzberger, Austria). The system operates at a speed of 4-5 m/s over a distance of approximately 120 meters using cushioned capsules. Transport duration ranges between 50 and 90 seconds. Blood sample transport performed manually by emergency department staff carrying the tube on foot from the phlebotomy area to the central clinical laboratory. Transport is dispatched simultaneously with the paired pneumatic tube sample. |
|
Annen: Personnel-First Sequence
Participants from whom two yellow-cap serum separator blood tubes are drawn simultaneously. Tube #1 (first drawn) is transported by manual personnel, and Tube #2 (second drawn) is transported via the pneumatic tube system (PTS). Both tubes are dispatched simultaneously. |
Blood sample transport using the Sumetzberger Power Control pneumatic tube system (Sumetzberger, Austria). The system operates at a speed of 4-5 m/s over a distance of approximately 120 meters using cushioned capsules. Transport duration ranges between 50 and 90 seconds. Blood sample transport performed manually by emergency department staff carrying the tube on foot from the phlebotomy area to the central clinical laboratory. Transport is dispatched simultaneously with the paired pneumatic tube sample. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Hemolysis Index (HI) Category in PTS-Transported vs. Personnel-Transported Tubes
Tidsramme: At laboratory analysis (within 30 minutes of blood draw)
|
Ordinal 6-category HI scale (0=<50, 1=50-99, 2=100-199, 3=200-299, 4=300-500, 5=>500 mg/dL free hemoglobin) as reported by the automated analyser. Higher category indicates more hemolysis. Compared between PTS and personnel tube from the same patient (paired). |
At laboratory analysis (within 30 minutes of blood draw)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of Clinically Significant Hemolysis (HI ≥ 1) in PTS-Transported vs. Personnel-Transported Tubes
Tidsramme: At laboratory analysis (within 30 minutes of blood draw)
|
Proportion of tubes with HI category ≥ 1 (free haemoglobin ≥ 50 mg/dL), the threshold at which samples are typically flagged for rejection by the laboratory. Dichotomous outcome (0 vs ≥1) compared between matched tube pairs. |
At laboratory analysis (within 30 minutes of blood draw)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Spearman Correlation Between Tube Transport Time and HI Category
Tidsramme: At laboratory analysis (within 30 minutes of blood draw)
|
Spearman rank correlation coefficient (ρ) between recorded PTS transport time (seconds, 50-90 s range) and the HI category of the PTS tube. Exploratory analysis. |
At laboratory analysis (within 30 minutes of blood draw)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Emir Ünal, Marmara University
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Mullins GR, Bruns DE. Air bubbles and hemolysis of blood samples during transport by pneumatic tube systems. Clin Chim Acta. 2017 Oct;473:9-13. doi: 10.1016/j.cca.2017.08.008. Epub 2017 Aug 10.
- Kara H, Bayir A, Ak A, Degirmenci S, Akinci M, Agacayak A, Marcil E, Azap M. Hemolysis associated with pneumatic tube system transport for blood samples. Pak J Med Sci. 2014 Jan;30(1):50-8. doi: 10.12669/pjms.301.4228.
- Cakirca G, Erdal H. The Effect of Pneumatic Tube Systems on the Hemolysis of Biochemistry Blood Samples. J Emerg Nurs. 2017 May;43(3):255-258. doi: 10.1016/j.jen.2016.09.007. Epub 2017 Mar 28.
- Phelan MP, Reineks EZ, Hustey FM, Berriochoa JP, Podolsky SR, Meldon S, Schold JD, Chamberlin J, Procop GW. Does Pneumatic Tube System Transport Contribute to Hemolysis in ED Blood Samples? West J Emerg Med. 2016 Sep;17(5):557-60. doi: 10.5811/westjem.2016.6.29948. Epub 2016 Jul 26.
- Ding X, Wen X, Wang L, Chen T, Zhou G, He H, Xin X. Effects of a pneumatic tube system on the hemolysis of blood samples: a PRISMA-compliant meta-analysis. Scand J Clin Lab Invest. 2021 Sep;81(5):343-352. doi: 10.1080/00365513.2021.1930140. Epub 2021 Jun 10.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MU-KAEK-2026-09.2029.26-0645
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data collected during the trial that underlie the published results will be made available upon reasonable request to qualified scientific researchers.
IPD-delingstidsramme
Data will become available beginning 3 months following publication and ending 36 months following article publication.
Tilgangskriterier for IPD-deling
Proposals should be submitted to the corresponding investigator via email (emirunal@gmail.com). Requestors must provide a methodologically sound research proposal and sign a data use agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .